AVAH Stock Forecast & Price Target

Aveanna Healthcare Hldgs is supported by a differentiated private-duty nursing platform that serves medically complex children, a protected and high-need patient base where home care costs roughly $500–600 per day versus $5,000–7,000 in acute care. Its growing preferred-payor mix improves reimbursement visibility and helps insulate the business from Medicaid budget pressure, while management raised long-term organic growth targets and now expects double-digit annual revenue growth including M&A. The outlook is further strengthened by a California Medi-Cal PDN rate increase effective January 2027 and the potential for 2026 adjusted EBITDA of $370.7MM, reflecting durable demand, margin expansion, and stronger free-cash-flow generation.

Aveanna Healthcare Hldgs is facing a negative outlook because the August 20th, 2026 secondary offering of 15,000,000 shares at $11.75 is entirely a shareholder sale, so the company receives no proceeds while the added supply can pressure sentiment. The bearish case is reinforced by labor headwinds, which are assumed to cut FY27 adjusted EBITDA by 10% in both downside scenarios, implying weaker operating leverage in a business already dependent on Medicaid and Medicaid MCO reimbursement. If legislative rate initiatives and the preferred payor strategy stall, valuation could compress to about 8x downside EBITDA, with scenarios implying $7 and even $5 per share.